Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Gerben Duns, PhD, Elena Viganò, PhD, Daisuke Ennishi, MD PhD, Clementine Sarkozy, MD, Stacy Hung, Elizabeth Chavez, Katsuyoshi Takata, MD PhD, Anja Mottok, MD PhD, Randy D. Gascoyne, MD, Ryan D. Morin, PhD, Kerry J Savage, BSc, MD MSc, David W. Scott, MBChB, PhD, Christian Steidl, MD

Blood (2019) 134 (Supplement_1): 922.

https://doi.org/10.1182/blood-2019-131450

Published: 2019

Journal Articles

Mutational Landscape of Grey Zone Lymphoma

Blood (2019) 134 (Supplement_1): 21.

https://doi.org/10.1182/blood-2019-127375

Published: 2019

Journal Articles

A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers

Blood (2018) 132 (Supplement 1): 1629.

https://doi.org/10.1182/blood-2018-99-118578

Published: 2018

Journal Articles

Prognostic Biomarkers Converge on a Germinal Centre Dark Zone Phenotype As a Determinant of Adverse Outcome in Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy

Anjali Silva, PhD MSc, BSc, Clementine Sarkozy, MD, Tracy Lackraj, PhD BSc, Anja Mottok, Vindi Jurinovic, MSc, Laurie H Sehn, MD MPH, Oliver Weigert, MD, Christian Steidl, MD, Robert Kridel, PhD MD

Blood (2018) 132 (Supplement 1): 4095.

https://doi.org/10.1182/blood-2018-99-112689

Published: 2018

Journal Articles

Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University

Guillaume Aussedat, Delphine Maucort-Boulch, MD PhD, Philippe Rey, MD, Violaine Safar, MD, Lionel Karlin, MD, Mad-Helenie Elsensohn, Msc, Laure Lebras, MD, Clementine Sarkozy, MD, Emmanuel Bachy, MD PhD, Bertrand Favier, PharmD, PhD, Nicolas Vantard, PharmD, Pierre Sesques, MD, Anne Lazareth, MD, Emmanuelle Ferrant, MD, Dana Ghergus, MD, Gilles Salles, MD PhD, Emmanuelle Nicolas-Virelizier, MD, Herve Ghesquieres, MD PhD

Blood (2018) 132 (Supplement 1): 4215.

https://doi.org/10.1182/blood-2018-99-116734

Published: 2018

Journal Articles

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Sara Alonso, MD, Martina Manni, PhD, Clementine Sarkozy, MD, Marielle Wondergem, MD, Attilio Guarini, MD, Laura Magnano, MD, Miguel Alcoceba, PhD, Martine E.D. Chamuleau, MD, Sara Galimberti, Maria Gomes da Silva, MD, Harald Holte, MD PhD, Emanuele Zucca, MD, Silvia Montoto, MD, Sandra Lockmer, MD, Igor Aurer, MD PhD, Luigi Marcheselli, MSc, Dolores Caballero, MD, Gilles Salles, MD PhD, Massimo Federico, MD

Blood (2018) 132 (Supplement 1): 4145.

https://doi.org/10.1182/blood-2018-99-115956

Published: 2018

Journal Articles

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Clementine Sarkozy, MD, Franck Morschhauser, MD, Jean-Marie Michot, MD, Benjamin Suttle, Lionel Karlin, MD, Steven LE Gouill, MD PhD, Fabrice Jardin, MD PhD, Herve Tilly, MD, Charles Herbaux, MD, Gilles Andre Salles, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 4191.

https://doi.org/10.1182/blood-2018-99-113193

Published: 2018

Journal Articles

Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center

Guillaume Aussedat, Hervé Ghesquières, MD PhD, Aspasia Stamatoullas, MD, Pierre Hirsch, MDPhD, Emmanuelle Nicolas-Virelizier, MD, Guillaume Cartron, Caroline Regny, Lionel Karlin, MD, Catherine Chassagne-Clément, MD, Violaine Safar, Nicolas Albin, MD, Antoine Deleuze, Alexis Lambour, Nicolas Daguindau, Christiane Copie, MDPhD, Richard Lemal, MD, Gilles Salles, MD PhD, Alexandra traverse-Glehen, MD PhD, Clementine Sarkozy, MD

Blood (2017) 130 (Supplement 1): 4149.

https://doi.org/10.1182/blood.V130.Suppl_1.4149.4149

Published: 2017

Journal Articles

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Clementine Sarkozy, MD, Alexandra Traverse-Glehen, MD PhD, Emmanuel Bachy, Lionel Karlin, MD, Hervé Ghesquières, MD PhD, Hervé Besson, Ruben Hermans, Nollaig Healy, Jamie Garside, Joris Diels, Finlay MacDougall, Corinna Pick-Lauer, Gilles Salles, MD

Blood (2017) 130 (Supplement 1): 2770.

https://doi.org/10.1182/blood.V130.Suppl_1.2770.2770

Published: 2017

Journal Articles

Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T 3 Phase IB Trial of the Lysa Group

Steven Le Gouill, MD PhD, Krimo Bouabdallah, MD, Barbara Burroni, MD, Thierry Lamy, MD PhD, Remy Gressin, MD, Guillaume Cartron, MD PhD, Catherine Thieblemont, MD PhD, Clémentine Sarkozy, MD, Corinne Haioun, MD PhD, Olivier Casasnovas, MD, Emmanuel Gyan, MD PhD, Olivier Hermine, MD PhD

Blood (2016) 128 (22): 2987.

https://doi.org/10.1182/blood.V128.22.2987.2987

Published: 2016

Journal Articles

Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas

Richard Delarue, MD, Jehan Dupuis, MD, Pierre Sujobert, MD PhD, Sarah Barbieux, MD, Ambroise Marçais, MD, Olivier Tournilhac, MD PhD, Florence Lachenal, MD, Morgane Cheminant, MD, Clementine Sarkozy, MD, Virginie Fataccioli, PhD, Franck Morschhauser, Olivier Hermine, MD PhD, Corinne Haioun, MD PhD, Philippe Gaulard, MD PhD, Francois Lemonnier, MD PhD

Blood (2016) 128 (22): 4164.

https://doi.org/10.1182/blood.V128.22.4164.4164

Published: 2016

Journal Articles

Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATE TM and RESONATE-2 TM with the French Lyon-Sud Database

Gilles A. Salles, Lucile Baseggio, PharmD, PhD, Emmanuel Bachy, MD PhD, Clementine Sarkozy, MD, Herve Ghesquieres, MD PhD, Joris Diels, PhD, Hervé Besson, PhD, Finlay MacDougall, BA, Ruben Hermans, PhD MSc, Nollaig Healy, PhD, Jamie Garside, MSc, Wafae Iraqi, PharmD, PhD, Evelyne Callet-Bauchu, MD PhD

Blood (2016) 128 (22): 2039.

https://doi.org/10.1182/blood.V128.22.2039.2039

Published: 2016

Journal Articles

Quantitative Assessment of Circulating Clonal IG-VDJ Sequences in Plasma of Follicular Lymphoma at Diagnosis Is Highly Predictive of Progression Free Survival (PFS)

Clémentine Sarkozy, MD, Sarah Huet, PharmD, PhD, Victoria Carlton, Alain Delmer, MD PhD, Fabrice Jardin, Marie-Helene Delfau-Larue, MD PhD, Malek Faham, Gilles Salles, MD PhD

Blood (2015) 126 (23): 2675.

https://doi.org/10.1182/blood.V126.23.2675.2675

Published: 2015

NARROW

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphomas with a Molecular PMBCL Expression Signature Represent a Distinct Molecular Subtype Associated with Poor Clinical Outcome

Mutational Landscape of Grey Zone Lymphoma

A New Simplified Prognostic Index Integrating the Type of Extra-Nodal Involvement and Age for Ann Arbor Stage IV Hodgkin Lymphoma Patients Diagnosed at TEP-Scanner Era: A Retrospective Analysis from Lymphoma Study Association (LYSA) Centers

Prognostic Biomarkers Converge on a Germinal Centre Dark Zone Phenotype As a Determinant of Adverse Outcome in Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy

Ritumixab in Combination with Adapted-Dose of Ifosfamide and Etoposide As Salvage Treatment in Elderly Refractory/Relapsed Diffuse Large B-Cell Lymphoma Patients Non-Candidate for High Dose Therapy: A Retrospective Study of Lyon Hospital University

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Results from a Phase Ib Evaluation of Tazemetostat (EPZ-6438) in Combination with R-CHOP in Poor Prognosis Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): a Lysa Study

Sequential Lymphoma between Classical Hodgkin Lymphoma and Diffuse Large B Cell Lymphoma: Clinicopathological Characteristics and Outcome of 18 Patients from Lysa Center

Comparative Effectiveness of Single-Agent Ibrutinib in the Ray Trial Versus Real-World Treatment in the Lyon-Sud Database in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Temsirolimus in Combination with Three Different Immuno-Chemotherapy Regimens in Relapse and Refractory Mantle Cell Lymphoma, Final Results of the T 3 Phase IB Trial of the Lysa Group

Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas

Single-Agent Ibrutinib Vs Standard of Care for Patients with Relapsed/Refractory (R/R) and Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): An Adjusted Comparison of RESONATE TM and RESONATE-2 TM with the French Lyon-Sud Database

Quantitative Assessment of Circulating Clonal IG-VDJ Sequences in Plasma of Follicular Lymphoma at Diagnosis Is Highly Predictive of Progression Free Survival (PFS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only